Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Zolpidem: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Oskykins
>Oskykins
Line 74: Line 74:
*'''[[Depressants]]''' (''[[1,4-Butanediol]], [[2-methyl-2-butanol]], [[alcohol]], [[barbiturates]], [[GHB]]/[[GBL]], [[methaqualone]], [[opioids]]'') - This combination can result in dangerous or even fatal levels of [[respiratory depression]]. These substances potentiate the [[muscle relaxation]], [[sedation]] and [[amnesia]] caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
*'''[[Depressants]]''' (''[[1,4-Butanediol]], [[2-methyl-2-butanol]], [[alcohol]], [[barbiturates]], [[GHB]]/[[GBL]], [[methaqualone]], [[opioids]]'') - This combination can result in dangerous or even fatal levels of [[respiratory depression]]. These substances potentiate the [[muscle relaxation]], [[sedation]] and [[amnesia]] caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
*'''[[Dissociatives]]''' - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
*'''[[Dissociatives]]''' - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
*'''[[Stimulants]]''' -  It is dangerous to combine benzodiazepines with [[stimulant]]s due to the risk of excessive intoxication. Stimulants decrease the [[sedation|sedative]] effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified [[disinhibition]] as well as [[benzodiazepine#Subjective effects|other effects]]. If combined, one should strictly limit themselves to only dosing a certain amount of benzodiazepines per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.
*'''[[Stimulants]]''' -  It is dangerous to combine zolpidem with [[stimulant]]s due to the risk of excessive intoxication. Stimulants decrease the [[sedation|sedative]] effect of zolpidem, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of zolpidem will be significantly increased, leading to intensified [[disinhibition]] as well as [[Zolpidem#Subjective effects|other effects]]. If combined, one should strictly limit themselves to only dosing a certain amount of zolpidem per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.


==Legal issues==
==Legal issues==

Revision as of 08:22, 2 June 2016

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Template:SubstanceBox/zolpidemZolpidem (Brand names Ambien, Intermezzo, Edluar, and Zolpimist[1]) is a non-benzodiazepine hypnotic used in the treatment of insomnia. [1][2] It is an imidazopyridine agonist of the GABAA receptor.[3]

Zolpidem is known colloquially as a "Z-drug." Other Z-drugs include zaleplon (Sonata) and zopiclone. They were initially thought to be less addictive and/or habit-forming than benzodiazepines. However, this appraisal has shifted somewhat in the last few years as cases of addiction and habituation have been presented. Zolpidem is recommended to be taken on a short-term basis. Daily or continuous use of the drug is not usually advised.

Chemistry

This chemistry section is incomplete.

You can help by adding to it.

Pharmacology

This pharmacology section is incomplete.

You can help by adding to it.

Zolpidem binds to GABAA receptor sites (close to benzodiazepine site) and facilitates chloride channel opening.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

The physical effects of zolpidem can be broken down into several components.

These are described below and generally include:

Cognitive effects

The cognitive effects of zolpidem can be broken down into several components.

It contains cognitive effects which generally include:

Visual effects

The visual effects of zolpidem can be broken down into several components.

Auditory effects

Toxicity and harm potential

Zolpidem has a low toxicity relative to dose.[4] However, it is [[Toxicity::potentially lethal when mixed with depressants like alcohol or opioids]].

It is strongly recommended that one use harm reduction practices when using this drug.

The acute oral LD50 in rats is 695 mg/kg.

Tolerance and addiction potential

Zolpidem is moderately addictive. A review of 36 human case reports found that reported dependence to zolpidem was lower than that of benzodiazepines.[5]

Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction.[6] For more information on tapering from zolpidem in a controlled manner, please see this guide while keeping in mind it is intended for benzodiazepines.

Although dependence builds up more slowly than in benzodiazepines, discontinuation from regular recreational doses of zolpidem appear to be as difficult as benzodiazepine discontinuation;[7] it is potentially life-threatening for individuals using regularly to discontinue use without tapering their dose over a period of weeks. There is also an increased risk of hypertension, seizures, and death.[8] Drugs which lower the seizure threshold such as tramadol should be avoided during withdrawal.

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

  • Depressants (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
  • Dissociatives - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
  • Stimulants - It is dangerous to combine zolpidem with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of zolpidem, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of zolpidem will be significantly increased, leading to intensified disinhibition as well as other effects. If combined, one should strictly limit themselves to only dosing a certain amount of zolpidem per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.
  • U.S.: Zolpidem is a Schedule IV drug due to evidence that the drug has addictive properties similar to benzodiazepines.
  • U.K.: The drug is prescription only.
  • Australia: Zopiclone is prescription only.

See also

References

  1. 1.0 1.1 http://www.drugs.com/zolpidem.html
  2. https://www.ncbi.nlm.nih.gov/pubmed/23462249
  3. http://www.rxlist.com/ambien-drug.htm
  4. zolpidem | C19H21N3O - PubChem | https://pubchem.ncbi.nlm.nih.gov/compound/zolpidem#section=Biological-Half-Life
  5. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data - http://onlinelibrary.wiley.com/doi/10.1046/j.1360-0443.2003.00491.x/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=
  6. Zolpidem at Supratherapeutic Doses can Cause Drug Abuse, Dependence and Withdrawal Seizure - http://www.japi.org/february2005/CR-139.pdf
  7. Zolpidem at Supratherapeutic Doses can Cause Drug Abuse, Dependence and Withdrawal Seizure - http://www.japi.org/february2005/CR-139.pdf
  8. A fatal case of benzodiazepine withdrawal. | http://www.ncbi.nlm.nih.gov/pubmed/19465812